Piper Sandler Reiterates Overweight Rating on Sutro Biopharma (STRO)

August 14, 2024 8:25 AM UTC Send to a Friend
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $11.00 price target on Sutro Biopharma (NASDAQ: STRO).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login